Big Pharma continues to introduce new osteoporosis drugs onto the market, even as more people are questioning their safety and choosing healthier lifestyle-based interventions to reduce fracture risk.
The latest osteoporosis drug on the market manufactured by Radius Health is abaloparatide, sold under the brand name Tymlos, a daily injectable drug that the Save Institute has been monitoring throughout its development.
Today we’ll show you what this drug is all about, its mechanism of action, its side effects, and more.
What Is Abaloparatide?
Abaloparatide is a synthetic sequence of amino acids designed to serve as an analog for human parathyroid hormone-related peptide (hPTHrP). This peptide stimulates osteoblasts to increase bone synthesis. That makes it different from the older osteoporosis drugs, bisphosphonates, that increase bone density by blocking osteoclasts that remove old bone.
A once-daily subcutaneous injection, abaloparatide is not recommended to be used for longer than two years, due to the risk of osteosarcoma or bone cancer (more on that later.)1
Abaloparatide is a laboratory-made anabolic protein mimicking naturally-occurring peptides that activate osteoblasts to increase bone formation.
Tymlos And Forteo
Tymlos is not the first drug of its kind. It activates the same parathyroid hormone pathways as Forteo (teriparatide), and thus functions in the same way. The key difference is that while Forteo is a recombinant human parathyroid hormone analog, Tymlos is a human parathyroid hormone-related peptide analog.
The recommended use of Tymlos is narrower than Forteo. Tymlos is generally only recommended in high-fracture risk cases with a history of osteoporotic fracture, or in which patients don’t respond to other osteoporosis drugs. Unlike Forteo, Tymlos is only recommended for women.2
It also has many of the same side effects as Forteo.
Tymlos functions in the same way as Forteo (teriparatide), by activating parathyroid hormone pathways. That means they have the same end result and many of the same risks.
A Close Look At The Fine Print
The clinical trials of Tymlos also revealed a slate of side effects and dangers associated with the drug.
The most alarming and serious risk is osteosarcoma, a form of bone cancer. Animal studies of abaloparatide revealed that the drug causes a dose-dependent increase in the incidence of osteosarcoma. The same is true of Forteo. As a result, neither drug is prescribed for more than two years, but the risk of osteosarcoma is acknowledged regardless of the length of use.3
Tymlos is not recommended for people already at risk of osteosarcoma due to Paget’s disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or certain radiation therapies.2
While bone cancer is the most dire potential side effect, it’s not the only one. Other side effects include:
- Palpitations and fast heartbeat
- Abdominal Pain
- Painful urination and blood in the urine
Once the prescribed course of Tymlos is completed, the manufacturers of Tymlos recommend taking alendronate (a bisphosphonate you may know as Fosamax) to maintain the newly accumulated bone.2 Alendronate comes with its own slew of different risks and side effects. That means that taking Tymlos results in needing to take more drugs.
It’s relevant to note that this year, the European Medicines Agency has rejected abaloparatide, stating that the drug’s benefits do not outweigh its risks.
Clearly, drugs are not a solution for osteoporosis.
Tymlos may cause osteosarcoma (bone cancer), as well as a host of other side effects.
Tymlos: One More Osteoporosis Drug You Should Avoid
Medications like Forteo and Tymlos promise to reverse osteoporosis, but their results are questionable, and many of their side effects extremely dangerous.
At the Save Institute, we maintain that the risks of osteoporosis drugs, including Tymlos, greatly exceed their questionable potential benefits. So we recommend staying away from osteoporosis drugs, and considering a natural, safe and effective osteoporosis reversal protocol.
1 “Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women.” Clinical Trial Results. Web: https://clinicaltrials.gov/ct2/show/study/NCT01343004?sect=X0123456
2 Tymlos Prescribing Information. Radius Pharmaceuticals. Web. http://radiuspharm.com/wp-content/uploads/tymlos/tymlos-prescribing-information.pdf
3 Vahle JL. “Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.” Toxicol Pathol. 2004 Jul-Aug;32(4):426-38. Web. https://www.ncbi.nlm.nih.gov/pubmed/15204966